Recommended Topic Related To:

Fentora

"Nov. 7, 2012 -- Statins -- widely prescribed drugs used to help prevent death from heart disease -- may play a role in reducing risk for cancer death, too, a new study shows.

Researchers followed all cancer patients in Denmark diagnos"...

Fentora

Side Effects
Interactions

SIDE EFFECTS

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of FENTORA has been evaluated in 304 opioid-tolerant cancer patients with breakthrough pain. The average duration of therapy was 76 days with some patients being treated for over 12 months.

The most commonly observed adverse events seen with FENTORA are typical of opioid side effects. Opioid side effects should be expected and managed accordingly.

The clinical trials of FENTORA were designed to evaluate safety and efficacy in treating patients with cancer and breakthrough pain; all patients were taking concomitant opioids, such as sustained-release morphine, sustained-release oxycodone or transdermal fentanyl, for their persistent pain.

The adverse event data presented here reflect the actual percentage of patients experiencing each adverse effect among patients who received FENTORA for breakthrough pain along with a concomitant opioid for persistent pain. There has been no attempt to correct for concomitant use of other opioids, duration of FENTORA therapy or cancer-related symptoms.

Table 2 lists, by maximum dose received, adverse events with an overall frequency of 5% or greater within the total population that occurred during titration. The ability to assign a dose-response relationship to these adverse events is limited by the titration schemes used in these studies.

Table 2: Adverse Events Which Occurred During Titration at a Frequency of ≥ 5%

System Organ Class MeDRA preferred term, n (%) 100 mcg
(N=45)
200 mcg
(N=34)
400 mcg
(N=53)
600 mcg
(N=56)
800 mcg
(N=113)
Total
(N=304)*
Gastrointestinal disorders
  Nausea 4 (9) 5 (15) 10 (19) 13 (23) 18 (16) 50 (17)
  Vomiting 0 2 (6) 2 (4) 7 (13) 3 (3) 14 (5)
General disorders and administration site conditions
  Fatigue 3 (7) 1 (3) 9 (17) 1 (2) 5 (4) 19 (6)
Nervous system disorders
  Dizziness 5 (11) 2 (6) 12 (23) 18 (32) 21 (19) 58 (19)
  Somnolence 2 (4) 2 (6) 6 (12) 7 (13) 3 (3) 20 (7)
  Headache 1 (2) 3 (9) 4 (8) 8 (14) 10 (9) 26 (9)
* Three hundred and two (302) patients were included in the safety analysis.

Table 3 lists, by successful dose, adverse events with an overall frequency of ≥ 5% within the total population that occurred after a successful dose had been determined.

Table 3: Adverse Events Which Occurred During Long-Term Treatment at a Frequency of ≥ 5%

System Organ Class MeDRA preferred term, n (%) 100 mcg
(N=19)
200 mcg
(N=31)
400 mcg
(N=44)
600 mcg
(N=48)
800 mcg
(N=58)
Total
(N=200)
Blood and lymphatic system disorders
  Anemia 6 (32) 4 (13) 4 (9) 5 (10) 7 (13) 26 (13)
  Neutropenia 0 2 (6) 1 (2) 4 (8) 4 (7) 11 (6)
Gastrointestinal disorders
  Nausea 8 (42) 5 (16) 14 (32) 13 (27) 17 (31) 57 (29)
  Vomiting 7 (37) 5 (16) 9 (20) 8 (17) 11 (20) 40 (20)
  Constipation 5 (26) 4 (13) 5 (11) 4 (8) 6 (11) 24 (12)
  Diarrhea 3 (16) 0 4 (9) 3 (6) 5 (9) 15 (8)
  Abdominal pain 2 (11) 1 (3) 4 (9) 7 (15) 4 (7) 18 (9)
General disorders and administration site conditions
  Edema peripheral 6 (32) 5 (16) 4 (9) 5 (10) 3 (5) 23 (12)
  Asthenia 3 (16) 5 (16) 2 (5) 3 (6) 8 (15) 21 (11)
  Fatigue 3 (16) 3 (10) 9 (20) 9 (19) 8 (15) 32 (16)
Infections and infestations
  Pneumonia 1 (5) 5 (16) 1 (2) 1 (2) 4 (7) 12 (6)
Investigations
  Weight decreased 1 (5) 1 (3) 3 (7) 2 (4) 6 (11) 13 (7)
Metabolism and nutrition disorders
  Dehydration 4 (21) 0 4 (9) 6 (13) 7 (13) 21 (11)
  Anorexia 1 (5) 2 (6) 4 (9) 3 (6) 6 (11) 16 (8)
  Hypokalemia 0 2 (6) 0 1 (2) 8 (15) 11 (6)
Musculoskeletal and connective tissue disorders
  Back pain 2 (11) 0 2 (5) 3 (6) 2 (4) 9 (5)
  Arthralgia 0 1 (3) 3 (7) 4 (8) 3 (5) 11 (6)
Neoplasms benign, malignant and unspecified (including cysts and polyps)
  Cancer pain 3 (16) 1 (3) 3 (7) 2 (4) 1 (2) 10 (5)
Nervous system disorders
  Dizziness 5 (26) 3 (10) 5 (11) 6 (13) 6 (11) 25 (13)
  Headache 2 (11) 1 (3) 4 (9) 5 (10) 8 (15) 20 (10)
  Somnolence 0 1 (3) 4 (9) 4 (8) 8 (15) 17 (9)
Psychiatric disorders
  Confusional state 3 (16) 1 (3) 2 (5) 3 (6) 5 (9) 14 (7)
  Depression 2 (11) 1 (3) 4 (9) 3 (6) 5 (9) 15 (8)
  Insomnia 2 (11) 1 (3) 3 (7) 2 (4) 4 (7) 12 (6)
Respiratory, thoracic, and mediastinal disorders
  Cough 1 (5) 1 (3) 2 (5) 4 (8) 5 (9) 13 (7)
  Dyspnea 1 (5) 6 (19) 0 7 (15) 4 (7) 18 (9)

In addition, a small number of patients (n=11) with Grade 1 mucositis were included in clinical trials designed to support the safety of FENTORA. There was no evidence of excess toxicity in this subset of patients.

The duration of exposure to FENTORA varied greatly, and included open-label and double-blind studies. The frequencies listed below represent the ≥ 1% of patients (and not listed in Tables 2 and 3 above) from three clinical trials (titration and post-titration periods combined) who experienced that event while receiving FENTORA. Events are classified by system organ class.

Adverse Events ( ≥ 1%)

Blood and Lymphatic System Disorders: Thrombocytopenia, Leukopenia

Cardiac Disorders: Tachycardia

Gastrointestinal Disorders: Stomatitis, Dry Mouth, Dyspepsia, Upper Abdominal Pain, Abdominal Distension, Dysphagia, Gingival Pain, Stomach Discomfort, Gastroesophageal Reflux Disease, Glossodynia, Mouth Ulceration

General Disorders and Administration Site Conditions: Pyrexia, Application Site Pain, Application Site Ulcer, Chest Pain, Chills, Application Site Irritation, Edema, Mucosal Inflammation, Pain

Hepatobiliary Disorders: Jaundice

Infections and Infestations: Oral Candidiasis, Urinary Tract Infection, Cellulitis, Nasopharyngitis, Sinusitis, Upper Respiratory Tract Infection, Influenza, Tooth Abscess

Injury, Poisoning and Procedural Complications: Fall, Spinal Compression Fracture

Investigations: Decreased Hemoglobin, Increased Blood Glucose, Decreased Hematocrit, Decreased Platelet Count

Metabolism and Nutrition Disorders: Decreased Appetite, Hypoalbuminemia, Hypercalcemia, Hypomagnesemia, Hyponatremia, Reduced Oral Intake

Musculoskeletal and Connective Tissue Disorders: Pain in Extremity, Myalgia, Chest Wall Pain, Muscle Spasms, Neck Pain, Shoulder Pain

Nervous System Disorders: Hypoesthesia, Dysgeusia, Lethargy, Peripheral Neuropathy, Paresthesia, Balance Disorder, Migraine, Neuropathy

Psychiatric Disorders: Anxiety, Disorientation, Euphoric Mood, Hallucination, Nervousness

Renal and Urinary Disorders: Renal Failure

Respiratory, Thoracic and Mediastinal Disorders: Pharyngolaryngeal Pain, Exertional Dyspnea, Pleural Effusion, Decreased Breathing Sounds, Wheezing

Skin and Subcutaneous Tissue Disorders: Pruritus, Rash, Hyperhidrosis, Cold Sweat

Vascular Disorders: Hypertension, Hypotension, Pallor, Deep Vein Thrombosis

Read the Fentora (fentanyl buccal tablet) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Fentanyl is metabolized mainly via the human CYP3A4 isoenzyme system; therefore potential interactions may occur when FENTORA is given concurrently with agents that affect CYP3A4 activity.

The concomitant use of FENTORA with CYP3A4 inhibitors (e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, telithromycin, aprepitant, diltiazem, erythromycin, fluconazole, grapefruit juice, verapamil, or cimetidine) may result in a potentially dangerous increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Patients receiving FENTORA who begin therapy with, or increase the dose of, CYP3A4 inhibitors should be carefully monitored for signs of opioid toxicity over an extended period of time. Dosage increase should be done cautiously [see WARNINGS AND PRECAUTIONS]. The concomitant use of FENTORA with CYP3A4 inducers (e.g., barbiturates, carbamazepine, efavirenz, glucocorticoids, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort, or troglitazone) may result in a decrease in fentanyl plasma concentrations, which could decrease the efficacy of FENTORA. Patients receiving FENTORA who stop therapy with, or decrease the dose of, CYP3A4 inducers should be monitored for signs of increased FENTORA activity and the dose of FENTORA should be adjusted accordingly.

Drug Abuse And Dependence

Controlled Substance

FENTORA contains fentanyl, a mu-opioid agonist and a Schedule II controlled substance with high potential for abuse similar to other opioids including hydromorphone, methadone, morphine, oxycodone, and oxymorphone. Fentanyl can be abused and is subject to misuse and criminal diversion.

Abuse

All patients treated with opioids require careful monitoring for signs of abuse and addiction, since use of opioid analgesic products carries the risk of addiction even under appropriate medical use.

Prescription drug abuse is the intentional non-therapeutic use of a prescription drug, even once, for its rewarding psychological or physiological effects.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated abuse of a prescription drug and include: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, and sometimes tolerance and/or physical dependence.

Abuse and addiction are separate and distinct from physical dependence and tolerance (see section 9.3). Physicians should be aware that addiction may not be accompanied by concurrent tolerance and physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.

Proper assessment of patients, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Abuse of FENTORA poses a risk of overdose and death. This risk is increased with concurrent abuse of FENTORA with alcohol and other substances.

FENTORA, like other opioids, may be diverted for non-medical use. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.

Dependence

Both tolerance and physical dependence can develop during chronic opioid therapy.

Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.

Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use. Withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug constitute evidence of physical dependence. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity, e.g., naloxone, nalmefene, or mixed agonist/antagonist analgesics (pentazocine, butorphanol, buprenorphine, nalbuphine). Clinically significant physical dependence may not occur until after several days to weeks of continued opioid usage.

FENTORA should not be abruptly discontinued [see DOSAGE AND ADMINISTRATION]. If FENTORA is abruptly discontinued, or the dosage is rapidly reduced, in a physically-dependent patient, an abstinence syndrome may occur. Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea; increased blood pressure, respiratory rate, or heart rate.

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms [see Use In Specific Populations].

Last reviewed on RxList: 3/12/2013
This monograph has been modified to include the generic and brand name in many instances.

Side Effects
Interactions
A A A

Fentora - User Reviews

Fentora User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Fentora sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.